Since the 1st of June 2022, the Long COVID Consortium, led by HUS Helsinki University Hospital, is working to elucidate the predisposing factors and mechanisms for the development of Long COVID Syndrome (LCS). This is essential to be able to develop and improve the care of patients suffering from the long-term effects of COVID-19 infection. Using real-world data from a hospital in China, the UC Riverside-led study found that individual characteristics, including age, weight, and additional illness determine which drug combinations most effectively reduce recurrence rates.